New publication: A roadmap to inform development, validation and approval of digital mobility outcomes: the Mobilise-D approach

Publications

Well known biomarkers such as blood pressure, respiration, temperature, pulse, and pain are frequently used by physicians and other health professionals to describe a patient’s health and disease status. In addition to these ‘signs of life’, there is another important aspect of people’s health and disease status, namely their mobility – how well they walk. Loss of physical mobility, such as reduced walking speed, is a significant feature of many health…

EMA Public Support for Mobilise-D

Other

In the first year of Mobilise-D, we asked the European Medicines Agency (EMA) for qualification advice for Digital Mobility Outcomes (DMOs). EMA just published their letter of support that publicly endorses our initial stage in the wider objective of the Mobilise-D Consortium to pursue the qualification of Digital Mobility Outcomes (DMOs) as monitoring biomarkers of…

NIHR NEWS: Monitoring patients’ mobility continues despite new lockdown

Technical Validation Study

Monitoring patients’ mobility during the COVID19 pandemic could easily have been impossible due to lockdown and restrictions such as social distancing. However, this isn’t the case for the Mobilise-D technical validation study (TVS) where 120 participants with chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, congestive heart failure or hip fracture, along with healthy older adults, will be enrolled. Our test sites in Newcastle and Sheffield have found a way to work around the distancing restrictions to keep the study open, and confirmed that the technical validation…